$1.91
2.14% yesterday
Nasdaq, Aug 12, 10:04 pm CET
ISIN
US2666051048
Symbol
DRRX

DURECT Corporation Stock price

$1.91
+1.35 241.01% 1M
+1.16 155.55% 6M
+1.16 154.67% YTD
+0.48 33.57% 1Y
-5.89 75.51% 3Y
-21.19 91.73% 5Y
-19.89 91.24% 10Y
-57.59 96.79% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.04 2.14%
ISIN
US2666051048
Symbol
DRRX
Industry

Key metrics

Basic
Market capitalization
$58.1m
Enterprise Value
$49.8m
Net debt
positive
Cash
$8.3m
Shares outstanding
31.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
12.0 | 57.2
EV/Sales
10.3 | 49.1
EV/FCF
negative
P/B
10.9
Financial Health
Equity Ratio
49.8%
Return on Equity
-91.2%
ROCE
-259.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.8m | $1.0m
EBITDA
$-17.2m | $-42.6m
EBIT
$-17.3m | $-17.8m
Net Income
$-4.9m | $-17.3m
Free Cash Flow
$-15.9m
Growth (TTM | estimate)
Revenue
-41.8% | -50.0%
EBITDA
45.4% | -126.4%
EBIT
45.1% | 5.7%
Net Income
78.9% | -107.5%
Free Cash Flow
50.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-355.7% | -4,200.6%
EBIT
-357.8%
Net
-101.4% | -1,700.0%
Free Cash Flow
-327.6%
More
EPS
$-0.2
FCF per Share
$-0.5
Short interest
1.3%
Employees
21
Rev per Employee
$100.0k
Show more

Is DURECT Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

DURECT Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a DURECT Corporation forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a DURECT Corporation forecast:

Hold
57%
Sell
43%

Financial data from DURECT Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4.84 4.84
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.92 9.92
26% 26%
205%
- Research and Development Expense 8.15 8.15
67% 67%
168%
-17 -17
45% 45%
-356%
- Depreciation and Amortization 0.10 0.10
150% 150%
2%
EBIT (Operating Income) EBIT -17 -17
45% 45%
-358%
Net Profit -4.91 -4.91
79% 79%
-101%

In millions USD.

Don't miss a Thing! We will send you all news about DURECT Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DURECT Corporation Stock News

Neutral
PRNewsWire
about 9 hours ago
Bausch Health will pay $1.75 per share plus up to $350 million in aggregate sales milestones Transaction expected to close in the third quarter of 2025 CUPERTINO, Calif. , Aug. 12, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the second quarter ended June 30, 2025 and provided an update on the previously announced acquisition of DURECT by Bausch H...
Neutral
Business Wire
15 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of DURECT Corporation (NASDAQ: DRRX) to Bausch Health Companies Inc. for $1.75 per share is fair to DURECT shareholders. Halper Sadeh encourages DURECT shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060...
Neutral
Business Wire
15 days ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating DURECT (NYSE: DRRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bausch Health. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, sh...
More DURECT Corporation News

Company Profile

DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Head office United States
CEO James Brown
Employees 21
Founded 1998
Website www.durect.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today